Superiority Trials in Invasive Aspergillosis: A Harsh Reality Check With the IA-DUET (HOVON502) Trial
Clinical Infectious Diseases · 24.02.2025 · 80 (2) · 367-370
DOI: 10.1093/cid/ciae501 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 08.10.2024. Verfasst von Hanne Lamberink und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Section of Infectious Diseases and Department of Medical Microbiology and Infectious Diseases, Erasmus University Me…. Hauptthemen laut MEDLINE: Antifungal Agents, Azoles, Echinocandins, Aspergillosis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Belgian-Netherlands Funding of International Trials, ZonMw.
Abstract (Originalsprache)
The IA-DUET study aimed to compare azole-echinocandin combination therapy with azole monotherapy for invasive aspergillosis. Recruitment was hindered by patient ineligibility, competing studies, and guidelines favoring combination therapy when azole resistance was unknown. The low IA-attributable mortality suggests future trials may benefit from cluster randomization or composite endpoints to enhance efficiency.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Section of Infectious Diseases and Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center, Rotterdam, The Netherlands.
- Department of Hematology, Ghent University Hospital, Ghent, Belgium.
- Department of Hematology, University Hospitals Leuven, Leuven, Belgium.
- Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
- Department of Laboratory Medicine and National Reference Center for Mycosis, Excellence Center for Medical Mycology (ECMM), University Hospitals Leuven, Leuven, Belgium.
- Department of Internal Medicine, St Antonius Hospital, Nieuwegein, The Netherlands.
ORCID-Profile: Hanne Lamberink, Sammy Huygens, Robina Aerts, Katrien Lagrou, Tom Lodewyck, Laurens Nieuwenhuizen, Maarten F Corsten, Ine Moors, Sophie Servais, Julien De Greef, Maya Hites, Astrid Demandt, Alexander Schauwvlieghe, Bart Rijnders
Förderung
- Belgian-Netherlands Funding of International Trials
- ZonMw
Zitieren
APA
Lamberink, H., Huygens, S., Aerts, R., Lagrou, K., van Leeuwen-Segarceanu, E., Lodewyck, T., Nieuwenhuizen, L., Corsten, M. F., Moors, I., Servais, S., De Greef, J., Hites, M., Demandt, A., Schauwvlieghe, A., Maertens, J., & Rijnders, B. (2025). Superiority Trials in Invasive Aspergillosis: A Harsh Reality Check With the IA-DUET (HOVON502) Trial. Clinical Infectious Diseases, 80(2), 367-370. https://doi.org/10.1093/cid/ciae501
Vancouver
Lamberink H, Huygens S, Aerts R, Lagrou K, van Leeuwen-Segarceanu E, Lodewyck T, et al. Superiority Trials in Invasive Aspergillosis: A Harsh Reality Check With the IA-DUET (HOVON502) Trial. Clinical Infectious Diseases. 2025;80(2):367-370. doi:10.1093/cid/ciae501
BibTeX
@article{Lamberink2025,
author = {Lamberink, Hanne and Huygens, Sammy and Aerts, Robina and Lagrou, Katrien and van Leeuwen-Segarceanu, Elena and Lodewyck, Tom and Nieuwenhuizen, Laurens and Corsten, Maarten F and Moors, Ine and Servais, Sophie and De Greef, Julien and Hites, Maya and Demandt, Astrid and Schauwvlieghe, Alexander and Maertens, Johan and Rijnders, Bart},
title = {Superiority Trials in Invasive Aspergillosis: A Harsh Reality Check With the IA-DUET (HOVON502) Trial},
journal = {Clinical Infectious Diseases},
year = {2025},
volume = {80},
number = {2},
pages = {367--370},
doi = {10.1093/cid/ciae501}
}
EUVIMED